GSTM1 and anemia (phenotype): Regarding the secondary endpoint of anemia benefit in the SIMPLIFY-1 trial, at 24 weeks, 66.5% of the MF patients on momelotinib achieved or maintained transfusion independence (defined as absence of RBC transfusion and no Hb level below 8 g/dL in the previous 12 weeks) versus 49.3% on the ruxolitinib arm (nominal P < 0.001); at 48 weeks, the corresponding transfusion-independence rates for patients on momelotinib from the outset and those who crossed over from the ruxolitinib arm to momelotinib after the 24-week randomized treatment period were 75% and 67%, respectively [91].